Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Antibody Development	317.79M	175.87M	126.89M	88.61M	41.09M
Antibody Development Growth	80.70%	38.60%	43.20%	115.62%	-
Gene Editing	72.08M	74.33M	61.08M	51.15M	68.89M
Gene Editing Growth	-3.02%	21.69%	19.41%	-25.75%	-
Animal Models Selling	389.21M	272.81M	202.26M	128.66M	85.06M
Animal Models Selling Growth	42.67%	34.88%	57.20%	51.25%	-
Elimination of Inter-Segment	-	-	-32.93M	-21.10M	-19.12M
Pre-Clinical Pharmacology and Efficacy Evaluation	200.99M	193.40M	176.07M	105.61M	75.38M
Pre-Clinical Pharmacology and Efficacy Evaluation Growth	3.93%	9.84%	66.72%	40.11%	-
Others	383.00K	516.00K	522.00K	1.64M	2.24M
Others Growth	-25.78%	-1.15%	-68.19%	-26.71%	-
Total	980.45M	716.91M	533.88M	354.56M	253.54M
Total Growth	36.76%	34.28%	50.58%	39.84%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
The PRC	318.20M	308.61M	287.74M	219.00M	162.71M
The PRC Growth	3.11%	7.25%	31.39%	34.60%	-
The United States of America (USA)	494.39M	301.17M	178.99M	102.12M	62.89M
The United States of America (USA) Growth	64.16%	68.26%	75.28%	62.37%	-
Others	167.87M	107.13M	67.15M	33.44M	12.34M
Others Growth	56.69%	59.54%	100.81%	171.03%	-
Korea	-	-	-	-	15.61M
Total	980.45M	716.91M	533.88M	354.56M	253.54M
Total Growth	36.76%	34.28%	50.58%	39.84%	-

Source: S&P Global Market Intelligence.